Founded November 2012
Investor The Trendlines Group, B. Braun, private investment funds (China and Canada), private investors, including key opinion leaders (surgeons)
CEO Zvi Peer
The TroClose 1200 offers surgeons a simple, secure, and safe solution to open and close the abdominal wall during laparoscopic procedures.
Instead of inserting closure sutures in the fascia at the end of a procedure, the TroClose 1200’s uniquely designed “two-in-one” port closure system efficiently inserts sutures into the tissue surrounding the cannula at the beginning of the procedure. When the cannula is removed, the surgeon closes the fascia by simply tying the TroClose 1200 sutures together.
Gordian’s TroClose 1200 can be adapted to all types of trocars: bladed/bladeless, disposable/multiuse, and others.
3 U.S. patents; one provisional, one in National phase
See Gordian’s achievement timeline.
See the TroClose 1200 product animation.
Gordian Surgical CEO Zvi Peer presents at Trendlines Showcase.
Serial entrepreneur with over 20 years’ experience in medical devices and biotechnology; co-founder and CEO, Romtec Electronics (successful IPO and exit); co-founder and CEO of biotech companies Fulcrum SP and BioGroup Technology (exit); CEO, QRay, a light therapy medical device company
Founder and CEO, Med-Tech Consultant Partners; years of experience in specialty medical devices, IP, regulatory, reimbursement; founder and former CEO multi-million-dollar specialty medical distribution company (later acquired)
Head of Surgery Department, Poriya Medical Center, Israel; vast experience in laparoscopic procedures
Engineer with more than 8 years’ experience in operations and logistics at HP Indigo and Lumenis; BSc, engineering, Ben-Gurion University of the Negev
18+ years of mechanical design, project management, and team leadership in the medical device sector. Previously, Director of Mechanical Engineering at XACT Robotics; managed the mechanical team at Medingo; BSc, mechanical engineering, Technion-Israel Institute of Technology
Director, Comprehensive Hernia Center, and Assistant Professor of Surgery, Johns Hopkins University School of Medicine; Assistant Professor, Biomedical Engineering; Associate Medical Director, Center for Bioengineering Innovation and Design (CBID) School of Engineering, Johns Hopkins University
Vice Chair and Professor, Department of Surgery; Director, Division of General Surgery, Storz Chair in MIS, Cedars-Sinai Medical Center; developed the laparoscopic technique of common bile duct exploration, laparoscopic splenectomy, and nipple ductoscopy
Early adopter and pioneer of therapeutic laparoscopic surgery, primary focus: MIS of the GI tract with special interest in inflammatory bowel disease; Professor of Surgery, Mount Sinai Health System; originated the Division of Laparoscopic Surgery; current Secretary, SAGES Foundation; President of the International Federation of Surgical Endoscopic Societies (IFSES)
Professor and Chairman, Department of Surgery, University of Buffalo School of Medicine and Biomedical Sciences; past president, SAGES
Director, Digestive Disease Center; Chairman, Department of Colorectal Surgery, Cleveland Clinic-Florida; past president, SAGES and American Society of Colon and Rectal Surgeons (ASCRS), regent, ACS
Vice-Chairman of the Department of Surgery at Florida International University, Herbert Wertheim College of Medicine in Florida; Surgeon at the Bariatric and Metabolic Institute at Jackson North Medical Center in Miami; Consultant for Minimally Invasive and Bariatric Surgery of Fundación Santa Fe de Bogotá, Colombia
An estimated 10 million laparoscopic procedures are performed annually. While laparoscopic surgeries are less invasive, closing abdominal access ports remains a difficult and time-consuming task. Today, surgeons manually suture ports with a needle and thread, adding up to 20 minutes per operation. Some surgeons use a dedicated closure device, rather than needle and thread, adding significantly to procedure cost and presenting safety problems.
The global trocar and closure markets are estimated at a combined US$1.45 billion yearly revenue (Medical Market and Technology Reports, MeddeviceTracker). According to MarketStrat, J&J dominates the trocar market (50%), followed by Covidien (30%) and Applied Medical (15%).